SyntheticGestalt, Enamine launch AI chemical data ecosystem

SyntheticGestalt and Enamine said August 3, 2026, they will build what they call the world’s largest experimentally validated AI-driven chemical data ecosystem, with initial support from Japan’s GENIAC program. The project is designed to speed drug discovery by pairing AI predictions with lab validation across 100 protein targets, with the dataset expected in 2027.

Why it matters: - The collaboration aims to close a major gap in AI drug discovery: high-quality experimental data. - The project is designed to turn AI-generated molecule predictions into validated chemical data at much larger scale. - The resulting dataset is intended to help researchers and drugmakers shorten discovery timelines that usually take years. - Japanese pharma partners are expected to be among the first beneficiaries.

What happened: - SyntheticGestalt and Enamine announced a collaboration on August 3, 2026, in Kyiv, Ukraine. - The companies said they will build the world’s largest experimentally validated AI-driven chemical data ecosystem. - GENIAC, a subsidy program backed by Japan’s Ministry of Economy, Trade and Industry and the New Energy and Industrial Technology Development Organisation, is providing strategic support. - SyntheticGestalt will analyze 100 industry-relevant protein targets and prioritize REAL Compounds for synthesis. - Enamine will run synthesis, protein production, activity assays and preclinical in vitro validation through its B-REAL discovery platform.

The details: - Enamine says its REAL space contains billions of highly feasible compounds and is integrated with high-throughput synthesis and on-site pharmacological and ADME/Tox testing. - The companies said the collaboration will generate hundreds of thousands of data points across 100 high-demand protein targets. - Enamine said its parallel synthesis platform can produce thousands of novel compounds in a few weeks. - The shared dataset is expected to be released in 2027. - The dataset is intended to serve the global scientific community, with an early focus on Japanese pharma partners. - Enamine’s public materials say the company has 4.8 million screening compounds in stock and 375,000 building blocks in stock. - Enamine REAL is described as containing trillions of synthetically feasible molecules, with synthesis in 3-4 weeks and over 80% feasibility. - Enamine says REAL compounds are created through 169 parallel synthesis protocols using 203,000 in-stock building blocks. - The company’s website is here. - More information on REAL is available in Enamine REAL.

Between the lines: - The partnership links predictive AI directly to lab execution, which is the bottleneck many drug-discovery efforts still face. - The scale matters because many AI models improve only when trained on large, experimentally grounded datasets. - The Japan connection suggests a national push to build domestic scientific infrastructure around generative AI and drug discovery. - The companies are positioning the project as a template for moving AI from molecule design to molecule validation.

What's next: - SyntheticGestalt and Enamine will move into target analysis, compound prioritization and synthesis. - The companies expect to release the dataset in 2027. - Japanese pharma and chemical companies are expected to gain first access to the resulting resource. - The companies said the platform could expand how AI and experimental science work together in drug discovery and other molecular applications.

The bottom line: - SyntheticGestalt and Enamine are betting that pairing AI prediction with industrial-scale validation will create a more usable foundation for faster drug discovery.